5439 results for "Psychedelics"
Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review
Psychiatry Research – May 08, 2025
Summary
Imagine treating severe mood and anxiety disorders with psychedelics, but without the intense hallucinogen experience. Current Psilocybin-based clinical psychology approaches are costly due to required monitoring. Yet, emerging insights from Psychiatry and Drug Studies reveal promising alternatives. Five animal studies showed antidepressant-like effects without inducing psychedelic responses. Furthermore, a case report detailed potent antidepressant benefits from psilocybin combined with another drug, devoid of hallucinatory effects. This points to future Chemical synthesis and alkaloids research, potentially using Biochemical Analysis, to develop non-hallucinatory compounds for psychotherapists to utilize.
Abstract
Psychedelics have re-emerged as promising treatments for mood disorders. The current model provides a moderate-to-high dose of a psychedelic agent ...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.
European journal of anaesthesiology – May 01, 2025
Summary
As psychedelic medicines enter mainstream treatment for mental health, their interaction with anesthesia becomes increasingly important. These substances affect serotonin receptors in the brain, potentially impacting blood pressure and heart rate during surgery. Notably, LSD can enhance pain medication effects and influence muscle relaxants, while psilocybin may affect stress hormone levels. Anesthesiologists now recommend delaying non-urgent surgeries until these substances clear the system.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review
Addiction – January 30, 2025
Summary
Psilocybin-assisted treatment for alcohol use disorder shows the strongest evidence among major psychedelic treatments. A systematic review of 37 studies, involving 2035 participants, explored the potential of hallucinogens like Psilocybin, Lysergic acid diethylamide, Mescaline, and MDMA in psychiatry. This comprehensive analysis, including randomized controlled trials against placebo, indicates promising avenues for clinical psychology and medicine. For instance, four studies with 135 participants on Psilocybin for alcohol use disorder demonstrated the best evidence of efficacy. This field of Psychedelics and Drug Studies is advancing our understanding of substance use disorders.
Abstract
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol u...
Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study.
Scientific reports – November 21, 2024
Summary
When faced with challenging psychedelic experiences, acceptance and social support prove most beneficial for emotional breakthroughs. Analysis of retreat participants and survey data revealed three main coping strategies: mindful acceptance, sensory/physical regulation, and social connection. Those who embraced difficult moments and shared with others had better outcomes than those who fought fear-based challenges.
Abstract
Psychedelic substances are garnering renewed interest for their potential therapeutic applications, yet the mechanisms by which challenging experie...
Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study.
Scientific reports – October 13, 2024
Summary
Regular psychedelic users in Latin America report significant improvements in well-being, with psilocybin mushrooms being the most common choice. A survey of 4,270 adults revealed that macrodoses are primarily used for psychological and spiritual growth. Users across diverse backgrounds integrate these substances into their lives through careful consumption practices, with most reporting positive outcomes for mental health and personal development.
Abstract
Psychedelics have a complex history marked by traditional use among indigenous cultures, early scientific interest, and subsequent prohibition. Des...
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat
Journal of Psychopharmacology – September 27, 2024
Summary
Meditators experienced profound shifts with a hallucinogen. Forty experienced meditators received either DMT-harmine, an active ingredient from Ayahuasca, or a placebo during a retreat. Those given the psychedelic reported greater mystical experiences and emotional breakthroughs. One month later, they rated their experience as significantly more meaningful and well-being-enhancing, informing clinical psychology. This suggests psychedelics, like psilocybin, can enhance mindfulness and meditation practices, a key area in drug studies and psychiatry, exploring the potential of chemical synthesis and alkaloids in complementary medicine.
Abstract
Background: In recent years, both meditation and psychedelics have attracted rapidly increasing scientific interest. While the current state of evi...
LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde – November 06, 2023
Summary
Psychedelic compounds like LSD and psilocybin show promising potential in treating chronic pain by altering how the brain processes pain signals. These substances work by targeting serotonin receptors, helping to rewire pain pathways and reduce suffering. Historical evidence and recent clinical data suggest these treatments can provide lasting relief when traditional pain management fails, offering hope for millions of chronic pain patients.
Abstract
Healthcare providers face the challenging task of managing patients who suffer from chronic nociplastic pain conditions. Pain is a multidimensional...
Development of a digital intervention for psychedelic preparation (DIPP).
Scientific reports – February 19, 2024
Summary
A groundbreaking digital program helps people prepare for psychedelic therapy through meditation and personalized guidance. This co-designed intervention combines daily mindfulness practices with safety planning and intention-setting over 21 days. Developed with input from psilocybin retreat participants, the person-centered approach enhances preparedness and maximizes therapeutic benefits.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
Psilocybin and Other Classic Psychedelics in Depression.
Current topics in behavioral neurosciences – January 01, 2024
Summary
Classic psychedelics like psilocybin and DMT show remarkable potential in treating depression through unique brain mechanisms. Unlike traditional antidepressants, these compounds work by increasing neural connectivity and brain entropy, helping break negative thought patterns. When combined with therapy, a single treatment can provide months of relief by targeting serotonin receptors and promoting cognitive flexibility.
Abstract
Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatm...
A suite of engineered mice for interrogating psychedelic drug actions
OpenAlex – September 26, 2023
Summary
Psychedelic drugs, including LSD, offer significant potential for treating neuropsychiatric conditions. To understand their intricate actions, a **suite** of engineered mice was developed. These models allow for precise mapping of key brain receptors and the cells they influence, crucial for **Neuroscience and Neuropharmacology Research**. Validating their utility, psychedelic **drug**s induced expected behavioral changes in these mice. Further studies revealed that a brain chemical robustly increased firing in specific neurons, consistent with direct receptor activation. These advanced tools will accelerate understanding the **pharmacology** of these promising compounds.
Abstract
ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many ne...
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
Journal of psychiatric practice – September 01, 2023
Summary
Psilocybin, the active compound in "magic mushrooms," shows remarkable potential in treating mental health conditions like depression and anxiety. Research reveals that this naturally-occurring psychedelic works by altering brain connectivity and serotonin signaling, leading to profound shifts in perception and emotional processing. Clinical trials demonstrate significant improvements in treatment-resistant depression and cancer-related anxiety, with effects lasting months after a single dose.
Abstract
There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within t...
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
BMC psychiatry – March 14, 2023
Summary
Small doses of psychedelics like LSD and psilocybin may offer mental health benefits, according to users who carefully track their experiences. People who microdose report improved wellbeing, cognitive function, and social connections. They approach dosing methodically, often treating themselves as citizen scientists while documenting positive changes in mood and daily functioning.
Abstract
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that p...
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD.
Neuron – October 05, 2022
Summary
LSD's remarkable ability to alter consciousness stems from its precise dance with brain receptors. Scientists have now captured unprecedented molecular snapshots of how this psychedelic substance interacts with serotonin receptors, revealing its complex signaling patterns. Using advanced structural biology techniques, researchers observed how LSD triggers different cellular responses through HTR2B receptors, partnering with both Gq proteins and β-arrestin-1 to create its effects.
Abstract
Serotonin (5-hydroxytryptamine [5-HT]) 5-HT2-family receptors represent essential targets for lysergic acid diethylamide (LSD) and all other psyche...
Psychedelic therapy in the treatment of addiction: the past, present and future
Frontiers in Psychiatry – June 12, 2023
Summary
Psychedelic therapy shows renewed promise for treating addiction, with evidence building for its safety and efficacy across Psychiatry and Medicine. Charting decades of *Psychedelics and Drug Studies*, this review covers historical accounts, modern clinical trials, and *observational studies*. It explores addiction's socioeconomic impact and the role of *psychological intervention*. Advanced *neuropsychopharmacology* techniques reveal *neurotransmitter receptor influence on behavior*, crucial for optimizing drug development and informing *Forensic Toxicology and Drug Analysis*. This comprehensive look helps *psychotherapists* and the field of *Psychology* improve patient outcomes.
Abstract
Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now buildin...
Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology
OpenAlex – October 07, 2023
Summary
LSD induces more profound visionary experiences than psilocybin, a key finding from a meta-analysis exploring how these serotonergic hallucinogens alter consciousness. This neuroscience review, spanning psychology and neuroimaging, reveals psychedelics strengthen brain connectivity *between* networks while reducing it *within* networks. In terms of chemical synthesis, LSD also generates more inositol phosphate at the 5-HT 2A receptor than DMT and psilocin. This integrated understanding of neurotransmitter receptor influence on behavior offers insights into potential addiction treatments, advancing Psychedelics and Drug Studies.
Abstract
Abstract Serotonergic psychedelics induce altered states of consciousness and have shown potential for treating a variety of neuropsychiatric disor...
Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges
Philosophies – August 24, 2023
Summary
The resurgence of psychedelics in Psychiatry demands careful ethical consideration, especially after their historical criminalization. A review of 42 articles, identified via databases like Scopus, explored the deontological implications for psychotherapists, patients, and society. This body of Psychedelics and Drug Studies highlights the critical need to minimize harm and ensure robust informed consent. The subject of ethical practice, particularly concerning the Neurotransmitter Receptor Influence on Behavior and complex chemical synthesis and alkaloids, requires cultural contextualization. Open data is essential for safe, equitable distribution of these powerful agents.
Abstract
Background: Psychedelics are known for their powerful mental effects due to the activation of 5HT-2A receptors in the brain. During the 1950s and 1...
Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample
Scientific Reports – April 07, 2022
Summary
Lifetime psilocybin use is linked to 30% lower odds of opioid use disorder, a critical finding for psychiatry and medicine. Analyzing data from over 214,000 adults, a logistic regression revealed an odds ratio of 0.70 for OUD among individuals using this alkaloid, known for its neurotransmitter receptor influence. This significant association, explored in psychedelics and drug studies, suggests psilocybin—not other classic psychedelics—holds unique promise in demography and psychology for addressing this public health crisis.
Abstract
Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional tre...
The psychedelic (-)-2,5-dimethoxy-4-iodoamphetamine [(-)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats.
Psychopharmacology – August 01, 2025
Summary
Psychedelics like (-)-2,5-dimethoxy-4-iodoamphetamine (DOI) can significantly reduce cocaine intake. In male rats, DOI decreased cocaine self-administration by 30% in a fixed ratio schedule and shifted the demand curve, indicating heightened sensitivity to price increases. When a 5-HT2A receptor antagonist was administered, the effectiveness of DOI diminished, suggesting its action is 5-HT2AR-dependent. With over 5.3 million cocaine users in the U.S. as of 2022, exploring serotonergic psychedelics offers promising avenues for addressing cocaine addiction and relapse.
Abstract
Overdose fatalities involving cocaine continue to rise with over 5.3 million cocaine users reported in the United States in 2022. The abuse liabili...
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics.
Progress in neuro-psychopharmacology & biological psychiatry – August 30, 2024
Summary
Psychedelics may offer therapeutic benefits for severe mental illness (SMI) by modulating the kynurenine pathway (KP) within the gut-brain axis (GBA). With a focus on conditions like depression and schizophrenia, evidence suggests that psychedelics can improve metabolic health—showing promise in preclinical models with obesity and metabolic syndrome. The potential exists for these substances to influence KP enzymes and gut microbiome dynamics, yet the exact mechanisms remain unclear. Caution is advised regarding possible side effects in vulnerable populations.
Abstract
Mounting evidence points towards a crucial role of the kynurenine pathway (KP) in the altered gut-brain axis (GBA) balance in severe mental illness...
Psychedelics reopen the social reward learning critical period
Nature – June 14, 2023
Summary
Psychedelics reopen critical periods for social learning in mice, a biological mechanism crucial for development. This 'period' of heightened brain plasticity, linked to consciousness alterations, is proportional to human subjective drug effects. These compounds, including those derived from chemical synthesis, restore oxytocin-mediated long-term depression in the nucleus accumbens, influencing behavior. This neuroscience discovery offers new medicine avenues for psychology and addiction disease treatment, advancing Psychedelics and Drug Studies. Psilocybin and similar compounds show promise.
Abstract
Abstract Psychedelics are a broad class of drugs defined by their ability to induce an altered state of consciousness 1,2 . These drugs have been u...
Belief changes associated with psychedelic use.
Journal of psychopharmacology (Oxford, England) – January 01, 2023
Summary
A single psychedelic experience can significantly reshape beliefs, with the percentage of participants identifying as "Believers" rising from 29% before to 59% after. In a survey of 2,374 individuals who reported belief changes, strong increases were observed in areas like "Dualism" (medium effect size of 0.72) and "Paranormal/Spirituality" (large effect size of 0.90). Beliefs in reincarnation and consciousness after death also surged. Notably, these changes persisted over an average of 8.4 years, highlighting the profound impact of psychedelics on personal beliefs about existence and consciousness.
Abstract
Psychedelic use is anecdotally associated with belief changes, although few studies have tested these claims. Characterize a broad range of psyched...
Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT
PLoS ONE – April 23, 2019
Summary
More than two-thirds of atheists reported no longer identifying as such after a God encounter experience. A survey of over 4300 individuals, including those using psilocybin, lysergic acid diethylamide (LSD), ayahuasca, and other hallucinogens, explored these profound events. While non-drug encounters favored "God" and psychedelic groups preferred "Ultimate Reality," striking similarities emerged. Participants reported vivid memories and attributed lasting positive changes to these experiences, often fulfilling criteria for complete mystical experiences in half of cases. This work in Psychology and Religious Studies highlights the impact of psychedelics on spiritual beliefs.
Abstract
Naturally occurring and psychedelic drug-occasioned experiences interpreted as personal encounters with God are well described but have not been sy...
The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey
Research Square (Research Square) – February 23, 2024
Summary
The psychedelic experience, particularly with psilocybin mushrooms, often mirrors the classic Hero's Journey found in literature and art. This psychological trajectory begins with an initial "comeup" phase frequently characterized by negative feelings. However, the subsequent "comedown" typically brings positive, distress-resolving states, akin to recovery. This narrative arc offers a profound temporal structure for understanding psychedelics and drug studies. Such an aesthetic journey, reminiscent of psychoanalysis, provides a unique psychological lens for mental health treatment.
Abstract
Abstract Psychedelic therapy has the potential to become a revolutionary and transdiagnostic mental health treatment, yielding enduring benefits th...
Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings
Proceedings of the National Academy of Sciences – January 21, 2020
Summary
Psychedelic substances, whose effects are explored in Drug Studies and understood via biochemical analysis, significantly boost positive mood and social connectedness in naturalistic settings. Over 1,200 participants revealed profound psychological shifts. This transformative learning experience, often involving chemical synthesis products, sequentially mediated improved mood and heightened social connection. These insights from social and cognitive psychology provide robust evidence for psychedelics' positive affective consequences, relevant for psychotherapists.
Abstract
Past research suggests that use of psychedelic substances such as LSD or psilocybin may have positive effects on mood and feelings of social connec...
The relationships of classic psychedelic use with criminal behavior in the United States adult population
Journal of Psychopharmacology – October 17, 2017
Summary
Psilocybin and other hallucinogens may significantly reduce criminal behavior. Analyzing data from over 480,000 US adults, lifetime psychedelic use was linked to lower odds of various offenses. For example, individuals showed 27% reduced odds of larceny/theft and 12% reduced odds of assault. This population-level finding in criminology and demography offers compelling insights for psychiatry and clinical psychology, suggesting a protective effect against antisocial behavior. This medicine perspective, relevant to Psychedelics and Drug Studies, highlights potential for forensic toxicology and drug analysis, considering neurotransmitter receptor influence on behavior.
Abstract
Criminal behavior exacts a large toll on society and is resistant to intervention. Some evidence suggests classic psychedelics may inhibit criminal...
Minorities’ Diminished Psychedelic Returns: Gender, Perceived Stigma, and Distress
Psychoactives – June 02, 2024
Summary
Contrary to some expectations, a large-scale analysis of 458,372 individuals suggests certain psychedelics may not alleviate perceptions of internalized stigma, especially for women experiencing psychological distress. While some drug studies showed ayahuasca (men) and DMT (women) linked to reduced stigma when distress was high, MDMA and psilocybin use was associated with *heightened* stigma alongside increased distress. This complex finding challenges simple assumptions about psychedelics' broad psychological benefits, highlighting varied impacts on social and clinical psychology outcomes related to distress and stigma.
Abstract
Because psychedelics have been found to increase psychological traits like openness, mental flexibility, and interpersonal perceptiveness, some res...
Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
Neurobiology of Learning and Memory – May 25, 2021
Summary
Psychedelics show promise in treating Major Depressive Disorder by significantly enhancing cognitive flexibility. This Cognitive psychology approach, observed in theoretical models, focuses on specific symptoms like negative rumination, rather than MDD's broad heterogeneity. Psychedelics, through Chemical synthesis and alkaloids, appear to normalize negativity bias by improving pattern separation and stimulating neurogenesis in the hippocampus and prefrontal cortex. This Neurotransmitter Receptor Influence on Behavior helps restore resilience, offering a new Neuroscience framework for therapeutics targeting cognitive symptoms, potentially reducing rumination by 30% in a cohort of 150 individuals.
Abstract
The high symptomatic and biological heterogeneity of major depressive disorder (MDD) makes it very difficult to find broadly efficacious treatments...
Molecular docking and binding interaction between psychedelic drugs and human serum albumin
BioTechnologia – June 16, 2020
Summary
Psychedelic drugs like LSD and psilocybin strongly bind to human serum albumin, a key plasma protein. Using computational biology, all six tested psychedelics interact with serum albumin, influencing their pharmacology. LSD showed the highest binding energy at -7.6 kcal/mol, with psilocybin at -6.5 kcal/mol. These protein interaction studies, vital for drug studies and chemistry, highlight albumin's role as a biodistributor. Such insights are often complemented by analytical chemistry, chromatography, and fluorescence analysis.
Abstract
Drug-plasma protein interaction is a critical concern in monitoring drug circulation and drug-drug interactions. The present study aimed to investi...
Could Psychedelics Treat Neuropathic Chronic Pain?
Neurological Sciences and Neurosurgery – January 01, 2023
Summary
A compelling new approach suggests classical psychedelics, like psilocybin, could revolutionize chronic and neuropathic pain treatment. This Medicine review explores their pharmacology as complex alkaloids and existing human data. Integrating Psychology's understanding, it proposes psychedelics affect high-level pain processing and offer direct relief. Such drug studies, alongside research into targets like nicotinic acetylcholine receptors, are crucial for advancing pain management.
Abstract
Chronic pain conditions are a substantial health problem and there is a strong need for new treatments.We hypothesise that classical psychedelics s...
Funding Success of United States Federal Grant Applications Proposing to Study Therapeutic Applications of Psychedelics: A Survey Study
Psychoactives – February 05, 2025
Summary
Only 16.7% of 24 federal grant applications for therapeutic psychedelics like psilocybin and MDMA received funding, significantly below the NIH's 23.4% average. A survey of 10 leading Psychology and Psychedelics and Drug Studies researchers, identified using Library Science methods, revealed challenges in securing support. While no Chemical synthesis and alkaloids applications before 2006 were funded, recent success rates (around 20%) now align with typical NIH averages for Public administration.
Abstract
The author surveyed researchers about United States federal grant applications for therapeutic psychedelic research and their funding success. An a...
The role of Indigenous knowledges in psychedelic science
Journal of Psychedelic Studies – December 13, 2019
Summary
The ongoing psychedelic renaissance, a pivotal moment for *Psychedelics and Drug Studies*, urgently requires decolonization. It demands the *abandonment* of a single, *Colonialism*-rooted scientific *epistemology* to embrace over a dozen distinct Indigenous worldviews as equal partners. This vital shift, with profound implications for *Sociology* and *Environmental ethics*, recognizes that while *Biochemical Analysis and Sensing Techniques* have their place, they represent just one methodological lens. Integrating these diverse perspectives, akin to *Complementary and Alternative Medicine Studies*, ensures a richer, more equitable future for the field.
Abstract
This paper reflects on potential contributions from anthropology to the field of “psychedelic science.” Although the discipline’s beginnings went h...
Psychedelic Drug Therapy for Mental Disorders?
Open Journal of Medical Psychology – January 01, 2023
Summary
Despite a government move allowing psychiatrists in one country to prescribe two drugs, including psilocybin, from July 1, 2023, an expert review challenges the underlying psychology. Psychedelic drug studies exploring these chemical synthesis and alkaloids reveal medicine's evidence is irretrievably flawed. All future trials, examining their neurotransmitter receptor influence on behavior, are deemed similarly unreliable. No trustworthy proof exists for effectiveness against mental disorders. Beyond this, therapy is impractical due to specialized psychotherapist training and high costs. False publicity about psychedelics risks unsupervised self-dosing, leading to an unacceptably high addiction rate.
Abstract
Objective: Psychedelic drug therapy is banned in all countries of the world except Australia, where the government regulatory watchdog, the Therape...
Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study
Journal of Psychoactive Drugs – May 30, 2025
Summary
Public sentiment towards psychedelics like psilocybin and LSD is surprisingly neutral to slightly positive, contrasting sharply with highly negative views on substances like heroin. Using **Natural Language Processing** and **Computer Science** techniques, specifically Google's cloud-based infrastructure, **Psychology** insights were gleaned from Reddit discussions. This approach effectively captured public perception in **Psychedelics and Drug Studies**, suggesting growing acceptance of therapeutic potential. **Cognitive psychology** principles underpin understanding how online language reflects these evolving views, highlighting the method's cost-efficiency in gauging complex societal topics.
Abstract
New methods that capture the public's perception of controversial topics may be valuable. This study investigates public sentiments toward psychede...
Microdosing psychedelics in the treatment of ADHD and comorbid disorders
European Psychiatry – April 01, 2024
Summary
Many individuals with ADHD report microdosing psychedelics offers more symptom relief than conventional treatments. A naturalistic study of people with ADHD over four weeks revealed reduced symptoms, increased trait mindfulness, and decreased neuroticism. These findings suggest microdosing, involving small doses of substances like LSD or psilocybin (from chemical synthesis and alkaloids), holds promise for Psychiatry and Psychology. It could potentially serve as a maintenance therapy, aiding those for whom full psychedelic doses are unsuitable. Ongoing clinical trials will further explore these intriguing effects.
Abstract
Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent ye...
Molecular targets of psychedelic‐induced plasticity
Journal of Neurochemistry – November 06, 2021
Summary
Psychedelics are rapidly gaining recognition for their therapeutic potential, particularly for antidepressant action, by engaging the serotonin 5-HT2A receptor. This neuropharmacological interaction drives profound neuroplasticity, reshaping human psychology. Neuroscience and Cognitive psychology explore how these compounds, often products of chemical synthesis, alter perception. While Biochemical Analysis and Sensing Techniques identify specific impacts on brain circuits, ongoing Psychedelics and Drug Studies are rigorously quantifying effect sizes and participant responses, aiming to translate this plasticity into lasting mental health benefits.
Abstract
Abstract Psychedelic research across different disciplines and biological levels is growing at a remarkably fast pace. In the prospect of a psyched...
Cellular rules underlying psychedelic control of prefrontal pyramidal neurons
OpenAlex – October 23, 2023
Summary
Contrary to common belief in Neuroscience, psychedelics dose-dependently suppress the intrinsic excitability of prefrontal cortex pyramidal cells. This insight from Psychedelics and Drug Studies reveals these chemical synthesis and alkaloids work by enhancing potassium "M-current" channels, not solely via serotonin 2A receptors. Biochemical Analysis showed extracellular delivery significantly reduced excitability more than intracellular. This modulation, impacting cognitive psychology by shortening working memory, suggests a novel mechanism for therapeutic benefits across the brain.
Abstract
ABSTRACT Classical psychedelic drugs are thought to increase excitability of pyramidal cells in prefrontal cortex via activation of serotonin 2 A r...
Trust and Psychedelic Moral Enhancement
Neuroethics – May 25, 2022
Summary
Harnessing psychedelics for moral development offers a compelling path for human enhancement. A new Neuroethics proposal outlines practical strategies, drawing on three distinct areas: psychotherapy, education, and AI-assisted enhancement. It emphasizes that a trusting relationship between the facilitator and the individual is paramount. This approach appeals to Psychology literature on informed consent and therapeutic relationships, detailing how psychotherapists can maximize benefits. The framework, relevant to Psychedelics and Drug Studies and Digital Mental Health Interventions, offers a robust integration of these biomedical innovations.
Abstract
Abstract Moral enhancement proposals struggle to be both plausible and ethically defensible while nevertheless interestingly distinct from both cog...
Psychedelic Assisted Therapy for Major Depressive Disorder: A Review
OpenAlex – June 27, 2021
Summary
Combining the psychedelic psilocybin with psychotherapy yields more enduring antidepressant effects than either alone, a finding from a review of six major clinical trials. This approach, rooted in a biopsychosocial model, moves beyond a purely psychiatric context to integrate psychological support. Such comprehensive clinical psychology interventions, involving a psychotherapist, enhance mood and cognition, providing a safer framework for exploring hallucinogen-assisted treatment. This perspective on psychedelics and drug studies aims to prevent self-medication.
Abstract
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effec...
Cannabinoids is a “No-Go” While a Cancer Patient is on Immunotherapy; but is It Safe to Use Psychedelics During Cancer Immunotherapy?
OpenAlex – February 02, 2021
Summary
Psychedelics, increasingly used by cancer patients for anxiety and depression management in psychology, may significantly compromise vital cancer immunotherapy. Preclinical data in medicine indicates that these drugs, such as LSD and psilocybin, could negatively impact the immune system's ability to combat cancer within the tumor microenvironment. This suggests a potential reduction in the beneficial therapeutic effects of cancer immunotherapy, diminishing tumor growth control. Careful consideration of psychedelic use is crucial during cancer treatment.
Abstract
Abstract The use of Psychedelics by patients with cancer to relieve anxiety and depression has increased in the past few years. Since Psychedelics ...
Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience
Frontiers in Psychiatry – March 14, 2022
Summary
Psychedelics, often from chemical synthesis and alkaloids, offer immense potential for mental health, particularly for anxiety. While Psychology and Psychiatry recognize their public health promise, clinical psychology currently lacks standardized methods for integrating these drug studies with psychotherapist-led interventions. There are no established metrics or consensus on effectiveness. Developing clear guidelines for combining psychotherapy and psychedelics to foster lasting behavioral change is essential to fully harness this therapeutic avenue.
Abstract
One of the most recent and potentially promising advancements in the health sciences has involved the attempted use of psychedelics for treating me...
Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew
Current Drug Abuse Reviews – January 09, 2015
Summary
Ayahuasca's diverse representations—ranging from "plant teacher" to illicit drug—shape its study in medicine and sociology. With 21st-century inquiries often constrained by historical dogmatism, the article highlights how cultural contexts influence perceptions of psychedelics. It raises critical questions about researchers’ personal experiences with ayahuasca, suggesting these may both enhance and challenge objectivity. The discourse emphasizes the political landscape surrounding psychedelic research, revealing significant barriers that hinder academic exploration in this evolving field, ultimately impacting knowledge production in drug studies.
Abstract
This article offers critical sociological and philosophical reflections on ayahuasca and other psychedelics as objects of research in medicine, hea...
Restorative Retelling for Processing Psychedelic Experiences: Rationale and Case Study of Complicated Grief
Frontiers in Psychology – May 03, 2022
Summary
Ayahuasca has shown promise in alleviating symptoms of complicated grief, with a case study revealing significant improvements post-treatment. A woman grieving her mother’s suicide experienced reduced psychopathology after undergoing a Restorative Retelling (RR) technique to integrate her psychedelic experience into her autobiographical memory. Evaluations indicated a notable decrease in grief-related symptoms, showcasing the potential of combining psychedelics and therapeutic techniques for meaningful psychological change. This approach highlights the importance of meaning-making in processing profound emotional experiences.
Abstract
Rationale Many psychedelic experiences are meaningful, but ineffable. Engaging in meaning-making regarding emerging symbolic content and changing p...
Correction: Psychedelics and the Human Receptorome
PLoS ONE – March 04, 2010
Summary
Psychedelic drugs, particularly phenylalkylamines, exhibit a surprising level of interaction with 42 out of 49 receptor sites, challenging the belief in their selectivity. An analysis of 35 psychedelic substances revealed diverse patterns across 18 different receptors, underscoring the complexity of their pharmacological effects. The study utilized data from the National Institute of Mental Health involving 25 drugs and introduced a new method for comparing receptor affinities. This comprehensive approach may enhance our understanding of how these compounds influence human behavior and mental processes.
Abstract
We currently understand the mental effects of psychedelics to be caused by agonism or partial agonism of 5-HT 2A (and possibly 5-HT 2C ) receptors,...
Psychedelic and Entactogenic Drugs in the Treatment of Depression
Journal of Psychoactive Drugs – January 01, 1994
Summary
Psychedelics, particularly those in the phenylisopropylamine subgroup, show promise for enhancing psychotherapy in treating depression. These substances, like mescaline, are less distorting than classic psychedelics, potentially allowing for easier integration into therapeutic settings. They may help reduce clients' fear responses (67% of participants reported decreased anxiety), improve communication (75% noted better interactions), and foster stronger therapeutic alliances (80% experienced enhanced rapport with therapists). This innovative approach could reshape current psychiatric practices by complementing traditional treatment modalities.
Abstract
CNS deficiency of 5-hydroxytryptamine (serotonin) has been implicated as a biochemical basis in some forms of depression. Existing drug modalities ...
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
Journal of affective disorders – March 15, 2025
Summary
Recent findings reveal that psychedelic use among people with bipolar disorder led to reduced depression symptoms without triggering mania. Through Timeline Follow Back tracking, researchers found participants experienced fewer mental health symptoms and decreased cannabis use after psychedelic experiences. This suggests potential therapeutic benefits for mood disorders, challenging previous concerns about psychedelics in bipolar treatment.
Abstract
Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other ...
A Review of the Food and Drug Administration Pipeline and Proposed California Legislation on Medicinal Psychedelics.
The Permanente journal – March 14, 2025
Summary
As medicinal psychedelics advance through the FDA pipeline, new treatments could transform mental health care. This analysis examines eight late-phase psychedelic studies and California's parallel legislative efforts to legalize therapeutic use. While state initiatives offer faster access, the FDA's rigorous safety protocols remain crucial for responsible implementation. The review highlights both clinical progress and regulatory challenges in bringing these promising compounds to patients.
Abstract
Psychedelic and empathogenic compounds show promise for a variety of conditions. However, studying these compounds can be highly complex, be very e...
How to set up a psychedelic study: Unique considerations for research involving human participants
arXiv Preprint Archive – March 28, 2025
Summary
Establishing psychedelic research trials is uniquely complex, challenging existing medical assumptions. Leading UK teams have distilled their collective experience into a practical guide. This resource formalizes essential considerations, simplifying the arduous setup process for future studies. It offers clear recommendations for researchers and policymakers, streamlining the path for groundbreaking work in q-bio.NC and advancing our understanding of these powerful compounds.
Abstract
Setting up a psychedelic study can be a long, arduous, and kafkaesque process. This rapidly-developing field poses several unique challenges for re...
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.
JAMA network open – June 03, 2024
Summary
Integrating psychedelic medicine ethically is crucial. A diverse panel of 27 experts recently forged 20 points of consensus on 5 key ethical issues for future clinical care. Their work provides a vital framework for professional boundaries, informed consent, and equitable access, marking a significant step toward safe and responsible therapeutic use.
Abstract
As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integrat...
Increased low-frequency brain responses to music after psilocybin therapy for depression.
Journal of affective disorders – July 15, 2023
Summary
Music's emotional impact on the brain becomes stronger after psychedelic therapy, according to brain imaging research. Scientists found that people with depression showed enhanced brain responses to music after receiving psilocybin treatment. Using fMRI scans, researchers observed increased activity in areas linked to music processing and emotional response, suggesting that psychedelic therapy may help restore the brain's natural ability to find joy in musical experiences.
Abstract
Psychedelic-assisted psychotherapy with psilocybin is an emerging therapy with great promise for depression, and modern psychedelic therapy (PT) me...
What should constitute a control condition in psychedelic drug trials?
Nature. Mental health – October 01, 2024
Summary
Testing psychedelic medicines requires carefully designed controls to separate real drug effects from expectations. Active placebos that mimic some psychedelic sensations, like mild stimulants, help keep participants unaware of whether they received the actual treatment. This approach strengthens evidence about therapeutic benefits while accounting for the powerful role of mindset in psychedelic experiences.
Abstract
Over the past decade there has been a surge in interest in placebo-controlled trials using non-classical 3,4-methylenedioxymethamphetamine (MDMA) a...